153 related articles for article (PubMed ID: 26679247)
1. Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi.
Palombi L; Pirillo MF; Marchei E; Jere H; Sagno JB; Luhanga R; Floridia M; Andreotti M; Galluzzo CM; Pichini S; Mwenda R; Mancinelli S; Marazzi MC; Vella S; Liotta G; Giuliano M
J Antimicrob Chemother; 2016 Apr; 71(4):1027-30. PubMed ID: 26679247
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of Option B+ ART in Malawi: few severe maternal toxicity events or infant HIV infections among pregnant women initiating tenofovir/lamivudine/efavirenz.
Harrington BJ; DiPrete BL; Jumbe AN; Ngongondo M; Limarzi L; Wallie SD; Chagomerana MB; Hosseinipour MC;
Trop Med Int Health; 2019 Oct; 24(10):1221-1228. PubMed ID: 31381233
[TBL] [Abstract][Full Text] [Related]
3. Levels of bone markers in a population of infants exposed in utero and during breastfeeding to tenofovir within an Option B+ programme in Malawi.
Floridia M; Liotta G; Andreotti M; Galluzzo CM; Amici R; Jere H; Sagno JB; Marazzi MC; Buonomo E; Scarcella P; Mancinelli S; Vella S; Giuliano M; Palombi L
J Antimicrob Chemother; 2016 Nov; 71(11):3206-3211. PubMed ID: 27494909
[TBL] [Abstract][Full Text] [Related]
4. Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi.
Galluzzo C; Liotta G; Andreotti M; Luhanga R; Jere H; Mancinelli S; Maulidi M; Sagno JB; Pirillo M; Erba F; Amici R; Ceffa S; Marazzi MC; Vella S; Palombi L; Giuliano M
J Med Virol; 2012 Oct; 84(10):1553-7. PubMed ID: 22930502
[TBL] [Abstract][Full Text] [Related]
5. Maternal Highly Active Antiretroviral Therapy and Child HIV-Free Survival in Malawi, 2004-2009.
Schwartz SR; Kumwenda N; Kumwenda J; Chen S; Mofenson LM; Taylor AW; Fowler MG; Taha TE
Matern Child Health J; 2016 Mar; 20(3):542-9. PubMed ID: 26525557
[TBL] [Abstract][Full Text] [Related]
6. Neurodevelopmental effects of ante-partum and post-partum antiretroviral exposure in HIV-exposed and uninfected children versus HIV-unexposed and uninfected children in Uganda and Malawi: a prospective cohort study.
Boivin MJ; Maliwichi-Senganimalunje L; Ogwang LW; Kawalazira R; Sikorskii A; Familiar-Lopez I; Kuteesa A; Nyakato M; Mutebe A; Namukooli JL; Mallewa M; Ruiseñor-Escudero H; Aizire J; Taha TE; Fowler MG
Lancet HIV; 2019 Aug; 6(8):e518-e530. PubMed ID: 31122797
[TBL] [Abstract][Full Text] [Related]
7. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.
; de Vincenzi I
Lancet Infect Dis; 2011 Mar; 11(3):171-80. PubMed ID: 21237718
[TBL] [Abstract][Full Text] [Related]
8. Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi.
Mancinelli S; Galluzzo CM; Andreotti M; Liotta G; Jere H; Sagno JB; Amici R; Pirillo MF; Scarcella P; Marazzi MC; Vella S; Palombi L; Giuliano M
AIDS Res Hum Retroviruses; 2016 Aug; 32(8):737-42. PubMed ID: 27067142
[TBL] [Abstract][Full Text] [Related]
9. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
10. Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs.
Waitt C; Olagunju A; Nakalema S; Kyohaire I; Owen A; Lamorde M; Khoo S
J Antimicrob Chemother; 2018 Apr; 73(4):1013-1019. PubMed ID: 29309634
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of Efavirenz 600 mg Once Daily During Pregnancy and Post Partum in Ghanaian Women Living With HIV.
Lartey M; Kenu E; Lassey A; Ntumy M; Ganu V; Sam M; Boamah I; Gilani FS; Yang H; Burch GM; Norman J; Peloquin CA; Kwara A
Clin Ther; 2020 Sep; 42(9):1818-1825. PubMed ID: 32811669
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety.
Palombi L; Pirillo MF; Andreotti M; Liotta G; Erba F; Sagno JB; Maulidi M; Ceffa S; Jere H; Marchei E; Pichini S; Galluzzo CM; Marazzi MC; Vella S; Giuliano M
Antivir Ther; 2012; 17(8):1511-9. PubMed ID: 22910456
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy.
Mirochnick M; Thomas T; Capparelli E; Zeh C; Holland D; Masaba R; Odhiambo P; Fowler MG; Weidle PJ; Thigpen MC
Antimicrob Agents Chemother; 2009 Mar; 53(3):1170-6. PubMed ID: 19114673
[TBL] [Abstract][Full Text] [Related]
14. Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption.
Mugwanya KK; Hendrix CW; Mugo NR; Marzinke M; Katabira ET; Ngure K; Semiyaga NB; John-Stewart G; Muwonge TR; Muthuri G; Stergachis A; Celum CL; Baeten JM
PLoS Med; 2016 Sep; 13(9):e1002132. PubMed ID: 27676257
[TBL] [Abstract][Full Text] [Related]
15. Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach.
Lamorde M; Schapiro JM; Burger D; Back DJ
AIDS; 2014 Nov; 28(17):2551-63. PubMed ID: 25574958
[TBL] [Abstract][Full Text] [Related]
16. Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi.
Palombi L; Galluzzo CM; Andreotti M; Liotta G; Jere H; Sagno JB; Luhanga R; Mancinelli S; Amici R; Marazzi MC; Vella S; Giuliano M
J Antimicrob Chemother; 2015 Oct; 70(10):2881-4. PubMed ID: 26111981
[TBL] [Abstract][Full Text] [Related]
17. Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV.
Palombi L; Marazzi MC; Voetberg A; Magid NA
AIDS; 2007 Jul; 21 Suppl 4():S65-71. PubMed ID: 17620755
[TBL] [Abstract][Full Text] [Related]
18. Uptake of prevention of mother-to-child-transmission using Option B+ in northern rural Malawi: a retrospective cohort study.
Price AJ; Kayange M; Zaba B; Chimbwandira FM; Jahn A; Chirwa Z; Dasgupta AN; Katundu C; Saul JL; Glynn JR; Koole O; Crampin AC
Sex Transm Infect; 2014 Jun; 90(4):309-14. PubMed ID: 24714445
[TBL] [Abstract][Full Text] [Related]
19. Growth and Neurodevelopment Outcomes in HIV-, Tenofovir-, and Efavirenz-Exposed Breastfed Infants in the PMTCT Option B+ Program in Malawi.
Kapito-Tembo AP; Bauleni A; Wesevich A; Ongubo D; Hosseinipour MC; Dube Q; Mwale P; Corbett A; Mwapasa V; Phiri S
J Acquir Immune Defic Syndr; 2021 Jan; 86(1):81-90. PubMed ID: 33027153
[TBL] [Abstract][Full Text] [Related]
20. Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial.
Chung MH; Kiarie JN; Richardson BA; Lehman DA; Overbaugh J; Kinuthia J; Njiri F; John-Stewart GC
Antivir Ther; 2008; 13(6):799-807. PubMed ID: 18839781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
